Xilio Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
This Form 8-K, dated January 19, 2024, reports a Nasdaq listing deficiency concerning Xilio Therapeutics’ common stock, traded under the symbol XLO on the Nasdaq Global Select Market. The company is an emerging growth company.
Financial and liquidity information
The filing does not provide revenue, earnings, cash flow, margin, debt, liquidity, or other operating financial metrics.
Material change versus the prior comparable period
On January 19, 2024, Nasdaq notified the company that its common stock had closed below the required minimum bid price of $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1). The notice had no immediate effect on the stock’s listing.
Outlook, risks, contingencies, and unusual items
- The company has an initial 180-calendar-day period, expiring July 17, 2024, to regain compliance.
- Compliance requires a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days, subject to possible Nasdaq discretion to extend the measurement period.
- If the company does not regain compliance during the initial period, it may be eligible for an additional 180-day period by transferring its listing to the Nasdaq Capital Market and satisfying applicable requirements.
- Nasdaq could ultimately issue a delisting determination if the deficiency is not cured or other listing standards are not met. The company may appeal such a determination to a Nasdaq Hearings Panel, but there is no assurance of a successful appeal or continued listing.
- Management intends to monitor the closing bid price and evaluate available options, but stated that there is no assurance the company will regain compliance.
Important facts for investors to verify
- Whether XLO regained the $1.00 minimum bid-price requirement by July 17, 2024, or received an extension.
- Whether Nasdaq required or approved a transfer to the Nasdaq Capital Market.
- Any subsequent Nasdaq delisting notice, appeal, reverse stock split, or other corporate action intended to restore compliance.
- The company’s financial condition and liquidity, which are not disclosed in this filing and should be reviewed in its periodic SEC reports.